General Control
1 known investors
General Control develops multiplexed epigenetic editors—programmable therapies that simultaneously control multiple genes to address complex diseases like Alzheimer's and sarcopenia. The company targets the biotechnology and therapeutic development sector, aiming to enable treatments that coordinate control of multiple disease-related nodes in a single therapy.
BiotechDeep Tech